Citadel Advisors
CLGN icon

Citadel Advisors’s CollPlant Biotechnologies CLGN Stock Holding History

Citadel Advisors’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20
Closed -$1.08K – 14361
2024
Q1 		$1.08K Sell
20
-160
-89% -$8.65K ﹤0.01% 14186
2023
Q4 		$11.5K Buy
+180
New +$9.85K ﹤0.01% 13041
2022
Q2 		– Sell
-1,170
Closed -$134K – 12980
2022
Q1 		$134K Buy
+1,170
New +$129K ﹤0.01% 11974

Other funds holding CLGN

PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $243M AUM 8.27% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's CLGN Position: Q2 2026 in Review

Citadel Advisors increased its CollPlant Biotechnologies (CLGN) stake by 67% in Q2 2026, buying an estimated $8.29K and bringing the position to 5,370 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #13418.

Citadel Advisors first reported a position in CLGN in Q3 2018 and has held it in 9 quarters since. The position peaked at $276K in Q2 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q2 2026.

  • Citadel Advisors held 5,370 shares of CollPlant Biotechnologies worth $18.7K as of Q2 2026.
  • Citadel Advisors bought 2,153 CollPlant Biotechnologies shares in Q2 2026, an estimated $8.29K.
  • CollPlant Biotechnologies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13418 holding.
  • Citadel Advisors first reported a position in CollPlant Biotechnologies in Q3 2018 and has held it in 9 quarters since.
  • Citadel Advisors's CollPlant Biotechnologies position peaked at $276K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.